Browse drugs

…201276042) of RCTs comparing SGLT2 inhibitors (dapagliflozin or empagliflozin) against placebo in HFpEF (LVEF >40%). To minimise reporting bi…

… kidney disease progression by 24% [HR 0.76; 95% CI 0.67–0.87]. Canagliflozin reduced the composite renal outcome [HR 0.66; 95% CI 0.53–0.81]…

…CI −0.53 to 0.86 events per 1000 person-years) or compared with DPP-4is (HR 0.94; 95% CI 0.71 to 1.24, rate difference −0.18; 95% CI −0…

… discussing urinary symptoms with patients prior to prescribing SGLT2is. Further research is critically needed to address these issues …